Emerging findings suggest that cervical noninvasive vagus nerve stimulation using the gammaCore device may represent an option with efficacy comparable to that of surgically implanted cervical vagus nerve stimulation, with a lower risk for side effects.
Researchers have proposed an update to the International Classification of Headache Disorders-3 criteria for headache attributed to transient ischemic attacks.
Fremanezumab, administered once monthly or once quarterly, is associated with greater reductions in monthly average migraine days than placebo in patients with difficult-to-treat migraine who did not respond to ≥2 of 4 classes of migraine preventative medications.
Telemedicine delivered over 1 year to patients with severe migraine-related disability was comparable to in-office visits for improving migraine disability, number of headache days, and average headache severity at 12 months.
A study highlights predictors of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA).
Women with migraine are more likely to present with worse performance of the cervical muscles, both in force production and muscle activity, compared with women without migraine.
Migraine is a potential risk factor for the development of traumatic brain injury (TBI) and is associated with a 78% increased risk for TBI compared with individuals without migraine.
